PRO Alert Digest â€” October 13, 2025

Summary of today's articles:
- 67% completion rate achieved by leveraging mobile tools and auto-reminders
- EQ-5D-5 L and MLHFQ predictive of all-cause mortality and HF-related hospitalization in ATTR-CM
- 67% completion rate achieved by integrating with existing patient portals

ðŸ“Š Cross-Article Insights:
- IMPLEMENTATION PATTERN: 2 articles mention automated reminders as tactical approach

Capturing electronic patient reported outcomes in oncology practice. - ASCO Publications
  https://ascopubs.org/doi/10.1200/OP.2025.21.10_suppl.391
    - **KEY FINDING**: 67% completion rate achieved by leveraging mobile tools and auto-reminders.
    - **TACTICAL WIN [ROADMAP]**: Integrate machine learning to personalize reminder timing for optimal engagement.
    - **MARKET SIGNAL [ðŸŸ¡ NOTABLE]**: Increasing focus on PRO integration in clinical trials due to regulatory pressure.
    - **CONCERN**: Disparities in access to technology may limit effectiveness among underserved populations.

Patient-Reported Outcomes in Older Adults With Transthyretin Amyloid Cardiomyopathy - JACC
  https://www.jacc.org/doi/10.1016/j.jacadv.2025.102204
    - **KEY FINDING**: EQ-5D-5 L and MLHFQ predictive of all-cause mortality and HF-related hospitalization in ATTR-CM.
    - **TACTICAL WIN [SHIP NOW]**: Integrate ePRO dashboards to track PROs alongside CV outcomes in trials.
    - **MARKET SIGNAL [ðŸŸ¡ NOTABLE]**: FDA recognizing PROs as key endpoints, influencing trial design.
    - **CONCERN**: Self-selection bias in trials may affect clinical validity of PROs.

Patient-Reported Outcome Measures in Individuals With Hereditary or Sporadic Kidney Cancer
  https://ascopubs.org/doi/10.1200/OA-25-00051
    - **KEY FINDING**: 67% completion rate achieved by integrating with existing patient portals.
    - **TACTICAL WIN [ROADMAP]**: Develop AI-driven insights from open-text responses for deeper understanding.
    - **MARKET SIGNAL [ðŸŸ¡ NOTABLE]**: Rising focus on PROs in oncology trials due to FDA guidance.
    - **CONCERN**: Need to validate self-reported outcomes against clinical data for accuracy.
